Inhibrx Biosciences, Inc. (INBX) Balance Sheet
As of 2026-06-30 (10-Q), Inhibrx Biosciences, Inc. (INBX) reported total assets of $154.2M, total liabilities of $207.2M and shareholders' equity of -$53.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $133.3M. Long-term debt: $176.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
INBXInhibrx Biosciences, Inc.Follow INBX — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 13 Nov, in 20 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|
| Cash and equivalents | 152.6 | 124.2 | 133.3 | |
| Current assets | 160.4 | 132.8 | 142.2 | |
| Total assets | 180.8 | 146.5 | 154.2 | |
| Current liabilities | 40.7 | 33.8 | 28.1 | |
| Long-term debt | 0.0 | 100.6 | 176.3 | |
| Total liabilities | 47.2 | 138.5 | 207.2 | |
| Shareholders' equity | 133.6 | 8.0 | -53.0 |
USD millions · SEC XBRL
Inhibrx Biosciences, Inc. — questions
- How much cash does Inhibrx Biosciences, Inc. have?
- $133.3M in cash and cash equivalents as of 2026-06-30.
- How much debt does Inhibrx Biosciences, Inc. have?
- $176.3M of long-term debt as of 2026-06-30.
- What are Inhibrx Biosciences, Inc.'s total assets?
- $154.2M as of 2026-06-30.
- What is Inhibrx Biosciences, Inc.'s shareholders' equity?
- -$53.0M as of 2026-06-30.
Every figure on this page comes from Inhibrx Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.